Today: 9 June 2026
Mastercard stock slips after Trump revives 10% credit-card cap talk; Brazil card suspension adds edge
22 January 2026
2 mins read

Mastercard stock slips after Trump revives 10% credit-card cap talk; Brazil card suspension adds edge

New York, Jan 21, 2026, 18:37 EST — Trading after-hours.

Shares of Mastercard Inc dropped roughly 0.8% on Wednesday and saw little movement after hours, following renewed White House scrutiny of the credit-card sector. The stock last changed hands at $527.57.

The recent surge has left payments stocks on edge, despite the fact that Mastercard doesn’t control credit-card interest rates—that’s up to the banks. Still, investors are lumping it all together, with headline risk driving the volatility.

Visa shares slipped roughly 0.2% late Wednesday. At the same time, American Express climbed around 2.1%, highlighting the market’s ongoing debate over who benefits if Washington moves ahead.

Trump said credit-card companies have been reaching out to him, and he’s urged them to “give people a break.” He also reiterated his demand that Congress impose a one-year cap on credit-card interest rates at 10%. He didn’t specify which companies or executives contacted him. Reuters

At Davos, JPMorgan Chase CEO Jamie Dimon slammed the proposal as an “economic disaster,” warning it would “remove credit from 80% of Americans” and have ripple effects far beyond the banking sector. Speaking separately, Trump said he’s urging Congress to cap rates at 10% for a year. Reuters

Bank shares took a hit a day earlier as investors sought clarity on whether a rate cap could be imposed without new legislation. “For now, it’s an overhang,” said Brian Jacobsen, chief economic strategist at Annex Wealth Management. Citigroup CEO Jane Fraser, speaking in Davos, emphasized affordability but warned that “capping rates would not be good for the U.S. economy,” Reuters reported. Reuters

Separately, Mastercard finds itself caught up in a rapid development in Brazil after the central bank ordered the liquidation of Will Financeira SA, linked to the struggling Banco Master. Mastercard confirmed it has suspended Will Bank cards from its network, citing missed settlement schedules—the deadlines for transaction payments within the system.

Mastercard is betting big on what it dubs “agentic commerce,” where AI agents handle shopping and payments for consumers. “Agentic commerce will only scale at the speed of trust,” said Sherri Haymond, Mastercard’s executive vice president of global digital commercialization, in an interview with Axios. The company also revealed it’s collaborating more closely with Google and Microsoft on checkout standards. Axios

On Wednesday, Mastercard revealed a partnership with Egypt’s credit bureau iscore to explore creating a new scoring model aimed at digital lending. This move is part of Mastercard’s broader push to expand its services and analytics beyond payments. “This collaboration with iscore represents a pivotal milestone in accelerating Egypt’s financial inclusion agenda,” said Selin Bahadirli, executive vice president at Mastercard. Mastercard

Traders face the risk that the rate-cap effort might stall and never become law, leaving the stock to swing wildly on political news while fundamentals remain steady. On the other hand, a policy shock could spook risk appetite ahead of earnings, turning payments stocks into a proxy battle over U.S. consumer policy.

Mastercard is set to release its fourth-quarter and full-year 2025 earnings on Jan. 29, followed by a conference call at 9 a.m. ET. Investors will be focused on updates regarding spending patterns, cross-border transaction demand, and potential impacts from political pressure on card fees that might affect volumes and revenue.

Stock Market Today

  • Docebo (TSX:DCBO) Valuation Story Shifts Amid Revised Earnings Guidance
    June 9, 2026, 10:40 AM EDT. Docebo's fair value remains at CA$35.97 despite updated financial models, reflecting a recalibration of valuation assumptions. Analysts highlight contrasting bullish views, citing a clear growth story backed by recent revenue guidance raising full-year 2026 estimates to US$271-275 million, against bearish concerns over limited analyst coverage and potential risks. The e-learning software provider forecast revenue of approximately US$65.4-65.6 million for Q1 2026, and US$66.7-66.9 million for Q2. At its Inspire 2026 event, Docebo unveiled a next-generation learning platform and key product updates, signaling strategic progress. Investors should monitor shifting assumptions and sector context amid evolving market narratives.

Latest articles

Autozi Shares Jump 400%, Filing Flags Risks for AZI

Autozi Shares Jump 400%, Filing Flags Risks for AZI

9 June 2026
Autozi Internet Technology shares soared over 400% to $5.69 in early Nasdaq trading after a 10-for-1 share consolidation slashed its share count to about 4.49 million, but the surge contrasts with a 63.1% revenue drop, 82.5% plunge in gross profit, and widened net loss, with the company warning of “substantial doubt” about its ability to continue as a going concern.
Redwire Shares Slip After $500 Million Stock Offering Filed

Redwire Shares Slip After $500 Million Stock Offering Filed

9 June 2026
Redwire Corp shares plunged 6.5% to $17.37 after launching a $500 million at-the-market stock program, raising dilution risks for investors as the company seeks flexible funding despite recent record backlog and strong revenue growth; the drop contrasted with gains at other space stocks, highlighting investor concern over potential share issuance.
Nuvalent Trades Close to $124 After GSK’s $10.6 Billion Offer

Nuvalent Trades Close to $124 After GSK’s $10.6 Billion Offer

9 June 2026
Nuvalent shares soared 38.9% to $122.93, just below GSK’s $124-a-share cash offer after the $10.6 billion buyout was announced, as investors bet on the deal closing with Nuvalent’s two lead lung-cancer drugs already under FDA review and a 40% premium to the last closing price driving the morning’s merger-arb trade.
Regentis Biomaterials Stock: Tiny RGNT Is Back In Focus Before The Bell

Regentis Biomaterials Stock: Tiny RGNT Is Back In Focus Before The Bell

9 June 2026
Regentis Biomaterials shares dipped 2 cents to $1.28 premarket after the company announced European surgeon training for its GelrinC knee implant will begin in Q3, marking a key commercial step but leaving investors waiting for revenue proof as the stock trades far below its $8 IPO price.
Palantir stock slips after hours as Davos deal headlines stack up; earnings next
Previous Story

Palantir stock slips after hours as Davos deal headlines stack up; earnings next

Applied Materials stock rebounds after tariff scare fades; what to watch next for AMAT
Next Story

Applied Materials stock rebounds after tariff scare fades; what to watch next for AMAT

Go toTop